

Appl. No. : 09/933,580
Filed : August 20, 2001

REMARKS

Claims 14-15 have been cancelled by the present amendment without prejudice to pursuing the subject matter thereof in a subsequent application. Independent Claim 20 has been added. Thus, Claims 13 and 20 are pending in the application. Applicants have carefully considered all of the remaining and pending rejections but respectfully assert that the pending claims are allowable over the Examiner's rejections for at least the reasons set forth below.

Rejections under § 112

The Examiner has rejected Claim 13-15 under 35 U.S.C. § 112, ¶ 1 for failing to comply with the enablement requirement. Claims 14-15 are now cancelled.

During the interview, independent Claim 13 was discussed. Claim 13 has been amended to be more clearly define the nature of the target protein, the proteins compared to the target protein, and the nature of the fingerprint comparison. Claim 13 is now directed to comparing a protein expressed in a pathogen with proteins expressed by the human genome. New Claim 20 is directed to comparing fingerprints of different proteins in the same genome, where the target protein is a target for one or more defined drug candidate molecules. These methods of using fingerprint annotations related to selecting targets for pharmaceutical intervention are described on pages 9 and 10 of the specification as filed.

It is respectfully submitted that the amendments to Claim 13 and new Claim 20 address the Examiner's concern as expressed in the Advisory Action that the claims should define more clearly how the fingerprint and the fingerprint comparisons relate to a pharmaceutical effect. Thus, it is respectfully submitted that the new claims are fully enabled by the specification as filed.

CONCLUSION

The Applicants respectfully submit that they have addressed all the Examiner's concerns by the amendments and remarks above. As such, the Applicants request that Claims 13 and 20 be allowed.

Appl. No. : 09/933,580


Filed : August 20, 2001

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 3/9/05

By: 

Thomas R. Arno
Registration No. 40,490
Attorney of Record
Customer No. 20,995
(619) 235-8550

1303145_1
030305